Medical Pharmacology: Chapter: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-07 — Deep Dive: Hypertension in Chronic Kidney Disease

Chapter: Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-07 — Deep Dive: Hypertension in Chronic Kidney Disease
Tier: Tier 3 — Clinical Vignettes

1. A 58-year-old man with a 15-year history of type 2 diabetes and hypertension presents for a nephrology consultation. His BP is 158/92 mmHg. Current medications: metformin 1000 mg twice daily and lisinopril 5 mg daily (started 3 months ago). Labs: eGFR 44 mL/min/1.73m2, creatinine 1.62 mg/dL (baseline was 1.38 mg/dL before lisinopril — a 17% rise), potassium 4.7 mEq/L, UACR 840 mg/g. His BP remains uncontrolled and his UACR has fallen from 840 to 580 mg/g (31% reduction). Which of the following represents the most appropriate next step in his pharmacological management?

A) Discontinue lisinopril — the 17% creatinine rise indicates early nephrotoxicity and the drug should be replaced with amlodipine to preserve renal function before irreversible damage occurs.
B) Add losartan 50 mg daily to lisinopril to achieve dual RAAS blockade, which will further reduce his UACR and provide additive renoprotection beyond single-agent RAAS inhibition.
C) Add spironolactone 25 mg daily to address his residual proteinuria and provide mineralocorticoid receptor blockade on top of lisinopril at this eGFR level.
D) Uptitrate lisinopril to 10 mg daily and add amlodipine 5 mg daily — the 17% creatinine rise is within the acceptable range confirming appropriate RAAS effect, the 31% UACR reduction is a favorable antiproteinuric response, and BP remains uncontrolled requiring additional antihypertensive therapy.
E) Add chlorthalidone 12.5 mg daily as the next antihypertensive step; the CLICK trial demonstrated meaningful BP reduction with chlorthalidone at this eGFR range and it will also reduce proteinuria through volume-dependent mechanisms.

ANSWER: D

Rationale:

This patient has three actionable findings: (1) a 17% creatinine rise that is within the acceptable range (up to 30–35%) and confirms intended RAAS hemodynamic effect, not nephrotoxicity; (2) a 31% UACR reduction confirming a favorable antiproteinuric response that predicts long-term renoprotection; and (3) uncontrolled BP at 158/92 mmHg requiring additional therapy. The correct response is to uptitrate lisinopril toward its maximum renoprotective dose and add a complementary antihypertensive — amlodipine is the preferred add-on given its efficacy, absence of renal dose adjustment requirements, and complementarity with RAAS inhibition (ACCOMPLISH paradigm).

Option A: Option A is incorrect because a 17% creatinine rise is well within the acceptable threshold; discontinuing lisinopril in a patient with a favorable antiproteinuric response would forfeit the established renoprotective benefit and expose him to accelerating CKD progression.
Option B: Option B is incorrect because dual RAAS blockade (ACEi plus ARB) is explicitly contraindicated in CKD by KDIGO 2021, with VA NEPHRON-D demonstrating excess AKI and hyperkalemia without renal benefit in this very patient profile.
Option C: Option C is incorrect because adding spironolactone to lisinopril at eGFR 44 with potassium already at 4.7 mEq/L carries significant hyperkalemia risk; if an MRA is to be added later, finerenone would be the preferred agent in diabetic CKD.
Option E: Option E is incorrect because while chlorthalidone has demonstrated BP-lowering benefit in CKD (CLICK trial), it is not the next priority step here — amlodipine is more appropriate as a first add-on to RAAS inhibition, and addressing BP control with the most evidence-based combination (RAAS inhibitor plus CCB) should precede consideration of a thiazide-like diuretic in this setting.

2. A 49-year-old woman with IgA nephropathy (IgAN) and CKD stage 2 (eGFR 72 mL/min/1.73m2) presents with BP 134/84 mmHg and UACR 680 mg/g. She has no diabetes. She is not currently on any antihypertensive therapy. Which of the following best represents first-line pharmacological management for this patient?

A) Start an ACE inhibitor or ARB at a low dose and uptitrate to the maximum tolerated dose; KDIGO 2021 strongly recommends RAAS inhibition as first-line therapy for CKD with UACR above 300 mg/g regardless of diabetes status, with a BP target below 130/80 mmHg, and the antiproteinuric benefit is independent of systemic BP lowering.
B) Start amlodipine 5 mg daily as first-line therapy — CCBs are preferred in non-diabetic CKD because they do not cause the creatinine rise associated with RAAS inhibitors, avoiding unnecessary alarm during monitoring.
C) Defer antihypertensive therapy until BP reaches 140/90 mmHg; her current BP of 134/84 mmHg does not yet meet the threshold for pharmacological intervention in non-diabetic CKD.
D) Start hydrochlorothiazide 25 mg daily; thiazide diuretics are first-line for hypertension in all patients with eGFR above 60 and should be used before RAAS inhibitors in non-diabetic CKD.
E) Start both an ACE inhibitor and an ARB simultaneously at low doses to achieve maximum initial antiproteinuric effect, then reduce to monotherapy once UACR falls below 300 mg/g.

ANSWER: A

Rationale:

This patient has CKD with severely increased albuminuria (UACR 680 mg/g) from IgA nephropathy, placing her in the highest-priority category for RAAS inhibition regardless of her non-diabetic status. KDIGO 2021 provides a Category A recommendation for ACE inhibitor or ARB as first-line therapy for all patients with CKD and UACR above 300 mg/g, based on robust evidence from the REIN trial (ramipril in non-diabetic proteinuric CKD) and multiple subsequent studies confirming BP-independent renoprotective benefit through efferent arteriolar dilation and anti-fibrotic mechanisms. Her BP of 134/84 mmHg also exceeds the ACC/AHA 2017 target of below 130/80 mmHg for CKD, providing a dual indication.

Option B: Option B is incorrect because amlodipine is not first-line in proteinuric CKD — it dilates the afferent arteriole and does not reduce intraglomerular pressure or proteinuria; it is an appropriate add-on after RAAS inhibition is established, not a substitute for it.
Option C: Option C is incorrect because the threshold for initiating therapy in proteinuric CKD is not a BP of 140/90 mmHg; KDIGO 2021 recommends RAAS inhibition for patients with UACR above 300 mg/g as a renoprotective measure independent of whether BP has reached a specific threshold, and her BP of 134/84 mmHg is already above the CKD target.
Option D: Option D is incorrect because thiazide diuretics, while useful for BP control in CKD, are not first-line before RAAS inhibitors in proteinuric non-diabetic CKD; they do not reduce intraglomerular pressure or proteinuria and lack the disease-modifying renoprotective evidence base of RAAS inhibition.
Option E: Option E is incorrect because dual RAAS blockade (ACEi plus ARB) is contraindicated in CKD regardless of the initial strategy or subsequent dose reduction plan — the VA NEPHRON-D evidence applies to all CKD patients, not just diabetic ones.

3. A 66-year-old man with CKD stage 3b (eGFR 32), hypertension, and type 2 diabetes is on ramipril 10 mg daily, amlodipine 10 mg daily, and furosemide 40 mg twice daily. His BP is 142/88 mmHg, potassium is 4.2 mEq/L, UACR is 520 mg/g, and HbA1c is 7.4%. His cardiologist wants to add an agent to further reduce his cardiovascular and renal risk. Which of the following additions is most strongly supported by current evidence?

A) Add bisoprolol 5 mg daily; beta-blockers reduce cardiovascular mortality in diabetic patients with CKD and their renoprotective effects in proteinuric CKD are established by multiple trials.
B) Add hydralazine 25 mg twice daily; direct vasodilators reduce afterload and intraglomerular pressure in patients with resistant hypertension and CKD when three-drug combinations have failed to control BP.
C) Add empagliflozin 10 mg daily; SGLT2 inhibitors are recommended for patients with type 2 diabetes and CKD (eGFR ≥20, UACR ≥200 mg/g) on background RAAS inhibition, with demonstrated reductions in cardiovascular death, ESRD, and CKD progression in this exact profile.
D) Add finerenone 10 mg daily before considering an SGLT2 inhibitor; current guidelines specify that finerenone must be added prior to SGLT2 inhibitor therapy in diabetic CKD to establish MRA baseline before introducing a second renoprotective class.
E) Add aliskiren 150 mg daily; the direct renin inhibitor provides a complementary point of RAAS blockade upstream of ACE inhibition and has demonstrated additive renoprotection in diabetic CKD without the AKI risk of dual ACEi/ARB combinations.

ANSWER: C

Rationale:

This patient's profile — type 2 diabetes, CKD stage 3b (eGFR 32), UACR 520 mg/g, on optimized RAAS inhibition — is precisely the population studied in CREDENCE and DAPA-CKD, and also overlaps with the EMPA-KIDNEY trial. SGLT2 inhibitors are now guideline-recommended (KDIGO 2022, ADA Standards of Care) for all patients with type 2 diabetes and CKD meeting these criteria, providing additive cardiovascular and renal protection on top of RAAS inhibition through complementary mechanisms — tubuloglomerular feedback restoration, natriuresis, and anti-fibrotic effects distinct from RAAS pathway inhibition. His eGFR of 32 is above the SGLT2 inhibitor initiation threshold of 20.

Option A: Option A is incorrect because while beta-blockers have cardiovascular mortality benefit in established HFrEF, their renoprotective effects in proteinuric CKD are not independently established by dedicated CKD outcome trials; beta-blockade is not the next evidence-based priority add-on in this patient.
Option B: Option B is incorrect because hydralazine dilates both afferent and efferent arterioles without selectively reducing intraglomerular pressure, and it is not an evidence-based renoprotective agent in diabetic CKD; it is used as a last-resort antihypertensive in resistant hypertension, not as the next step when BP is 142/88 mmHg on a three-drug regimen.
Option D: Option D is incorrect because no current guideline specifies that finerenone must precede SGLT2 inhibitor therapy in diabetic CKD; the sequencing of these two classes is not mandated, and SGLT2 inhibitors have a stronger and more replicated evidence base as the priority add-on after RAAS inhibition.
Option E: Option E is incorrect because aliskiren combined with an ACE inhibitor constitutes dual RAAS blockade; the ALTITUDE trial demonstrated excess AKI, hyperkalemia, and stroke with aliskiren added to ACEi or ARB in patients with type 2 diabetes and CKD or cardiovascular disease, leading to a regulatory contraindication for this combination.

4. A 74-year-old woman with CKD stage 4 (eGFR 22), hypertension, and a history of falls presents with BP 168/70 mmHg on amlodipine 10 mg daily and telmisartan 80 mg daily. Her potassium is 5.1 mEq/L and creatinine is stable. She reports dizziness on standing. Orthostatic BP measurement shows a drop from 168/70 mmHg supine to 134/58 mmHg standing — a 34 mmHg systolic drop. Which of the following is the most appropriate next management step?

A) Add furosemide 40 mg daily to address the volume-dependent component of her hypertension; loop diuretics are first-line for volume management in stage 4 CKD and will lower her supine BP without worsening orthostatic hypotension.
B) Before adding any antihypertensive, address the orthostatic hypotension — review and optimize volume status, assess contributing medications (timing of amlodipine and telmisartan relative to meals and activity), consider fludrocortisone if volume depletion is confirmed, and reassess the risk-benefit of further BP lowering given her fall history and the 34 mmHg orthostatic drop that already meets the definition of clinically significant orthostatic hypotension.
C) Add chlorthalidone 12.5 mg daily; the CLICK trial demonstrated BP reduction in stage 3–4 CKD and chlorthalidone will address the supine hypertension while the shorter duration of action compared to loop diuretics makes it safer in patients with orthostatic hypotension.
D) Add bisoprolol 2.5 mg daily; beta-blockers reduce supine hypertension through heart rate reduction without worsening orthostatic hypotension, making them the preferred next add-on in elderly CKD patients with orthostatic symptoms.
E) Uptitrate telmisartan to a higher dose is not possible at 80 mg as this is the maximum; instead add hydralazine 25 mg twice daily as a direct vasodilator, which specifically lowers supine BP without affecting the standing response because it acts on resistance vessels rather than capacitance vessels.

ANSWER: B

Rationale:

This patient already has clinically significant orthostatic hypotension — a 34 mmHg systolic drop on standing that is producing symptomatic dizziness — in addition to a fall history in an elderly woman with advanced CKD. Adding another antihypertensive before addressing the orthostatic problem risks precipitating a serious fall and injury. The correct clinical priority is to characterize and manage the orthostatic hypotension first: assess volume status (is she over-diuresed?), review medication timing and optimize administration timing relative to activity, consider whether the existing medications are contributing disproportionately to postural hypotension, and only then reassess whether further BP lowering is safe and appropriate given her individual risk profile. In frail elderly CKD patients, individualization of BP targets to account for orthostatic hypotension, fall risk, and functional status is a key principle of the KDIGO 2021 guideline.

Option A: Option A is incorrect because adding furosemide to a patient with symptomatic orthostatic hypotension and a 34 mmHg postural drop would likely worsen volume depletion and increase fall risk before addressing the underlying problem.
Option C: Option C is incorrect because chlorthalidone, while effective for BP reduction in CKD, would further lower BP in a patient already experiencing symptomatic orthostasis — adding it before addressing the postural problem is unsafe.
Option D: Option D is incorrect because bisoprolol's heart rate reduction does not specifically protect against orthostatic hypotension; beta-blockers can impair the compensatory tachycardia that normally limits the degree of orthostatic BP drop, potentially worsening rather than improving orthostatic symptoms.
Option E: Option E is incorrect because hydralazine's claim of selectively lowering supine BP without affecting the standing response is pharmacologically inaccurate — hydralazine dilates resistance arterioles and its effect on standing BP would be additive with existing agents; it is not an orthostatic-safe antihypertensive by mechanism.

5. A 52-year-old man with CKD stage 3a (eGFR 55), hypertension, and no diabetes is started on enalapril 5 mg daily. At 2-week follow-up his creatinine has risen from 1.3 to 2.1 mg/dL — a 62% increase. He has no symptoms, his BP is 124/76 mmHg, and his potassium is 5.0 mEq/L. Renal ultrasound shows bilateral small echogenic kidneys with no hydronephrosis. Which of the following is the most appropriate next step?

A) Continue enalapril at the current dose — a creatinine rise of any magnitude in the first 2 weeks after RAAS inhibitor initiation is always acceptable as part of the hemodynamic adaptation and will stabilize within 4 weeks without intervention.
B) Reduce enalapril to 2.5 mg daily and recheck creatinine in 1 week; the 62% rise exceeds the acceptable threshold and requires dose reduction rather than discontinuation, as the drug should be maintained at the lowest tolerated dose for ongoing renoprotection.
C) Add amlodipine 5 mg daily; the creatinine rise reflects over-lowering of systemic BP which has reduced renal perfusion pressure, and adding amlodipine will redistribute blood flow to the kidney through afferent dilation, reversing the creatinine rise.
D) Initiate urgent nephrology referral for renal biopsy — a 62% creatinine rise in 2 weeks indicates acute glomerulonephritis triggered by enalapril that requires histological confirmation before further management decisions are made.
E) Hold enalapril immediately, assess for contributing factors including volume depletion and NSAID use, check for bilateral renal artery stenosis given the bilateral small echogenic kidneys and the disproportionate creatinine rise, and recheck creatinine and electrolytes within 48–72 hours before deciding on restart.

ANSWER: E

Rationale:

A 62% creatinine rise is well above the acceptable threshold of 30–35% and requires immediate action — holding enalapril and investigating the cause. The bilateral small echogenic kidneys on ultrasound are a critical clue: this pattern is consistent with chronic parenchymal disease but raises the possibility of bilateral renovascular disease, including bilateral renal artery stenosis (RAS). Bilateral RAS is an absolute contraindication to RAAS inhibition because GFR in both kidneys depends on angiotensin II-mediated efferent constriction to maintain filtration pressure across the stenosed vessels — removing this compensation precipitates acute and potentially severe AKI. Importantly, the ultrasound did not include specific Doppler evaluation of the renal arteries. Given the disproportionate creatinine rise (62%), small bilateral kidneys, and the magnitude of BP response (now 124/76 from a presumably higher starting BP), bilateral RAS must be excluded before restarting enalapril. Contributing factors including volume depletion and NSAID use should also be assessed.

Option A: Option A is incorrect because a 62% creatinine rise is not always acceptable — it exceeds the acceptable threshold and requires drug cessation and investigation, not continuation.
Option B: Option B is incorrect because dose reduction is not the appropriate first step when creatinine has risen 62% — the drug should be held completely while the cause is investigated, particularly given the anatomical clues suggesting possible renovascular disease.
Option C: Option C is incorrect because adding amlodipine does not reverse a creatinine rise caused by RAAS inhibition-mediated loss of efferent tone; amlodipine acts on the afferent arteriole and would not restore the efferent arteriolar tone that was maintaining filtration.
Option D: Option D is incorrect because acute glomerulonephritis triggered by ACE inhibitors is not a recognized or common entity; the disproportionate creatinine rise here has a hemodynamic explanation (most likely bilateral RAS or significant volume depletion) that should be investigated before any consideration of biopsy.

6. A 61-year-old man with CKD stage 3b (eGFR 38), type 2 diabetes, and hypertension has been on losartan 100 mg daily, amlodipine 10 mg daily, and dapagliflozin 10 mg daily for 8 months. His UACR has fallen from 640 to 280 mg/g and his BP is 128/74 mmHg. His potassium is 4.3 mEq/L and eGFR has been stable. His endocrinologist now asks whether finerenone should be added. Which of the following best describes the role of finerenone in this patient's current regimen?

A) Finerenone should not be added because the patient is already on three renoprotective agents; adding a fourth creates polypharmacy that increases adverse event risk without proven additive benefit beyond the current triple combination.
B) Finerenone is contraindicated in patients already on dapagliflozin because the two agents both cause natriuresis, and their combination produces additive volume depletion that risks AKI in patients with eGFR below 45.
C) Finerenone should be added only if UACR rises back above 300 mg/g; since UACR has already fallen to 280 mg/g, the threshold for finerenone initiation has not been met and its addition is not currently indicated.
D) Finerenone should be considered as a further addition given his residual albuminuria of 280 mg/g and diabetic CKD on optimized RAAS and SGLT2 inhibitor therapy; the FIDELITY pooled analysis demonstrated cardiovascular and renal benefit across the full spectrum of CKD severity and albuminuria in type 2 diabetes, and the potassium of 4.3 mEq/L is below the prerequisite threshold of 5.0 mEq/L for initiation — this represents the emerging triple renoprotective strategy.
E) Finerenone should replace dapagliflozin rather than being added; the two agents have overlapping mechanisms of action and replacing dapagliflozin with finerenone provides equivalent renoprotection with fewer urinary side effects.

ANSWER: D

Rationale:

This patient represents the ideal candidate for finerenone as a third renoprotective agent — type 2 diabetic CKD with residual albuminuria (UACR 280 mg/g) despite optimized RAAS inhibition (losartan 100 mg) and SGLT2 inhibitor therapy (dapagliflozin), with potassium below 5.0 mEq/L and stable eGFR. The FIDELITY pooled analysis of FIDELIO-DKD and FIGARO-DKD demonstrated significant reduction in both cardiovascular and renal composite endpoints with finerenone across the full spectrum of CKD severity and albuminuria range studied (including patients with UACR 30–300 mg/g in FIGARO-DKD), supporting its use even with UACR below 300 mg/g in diabetic CKD. The combination of RAAS inhibitor plus SGLT2 inhibitor plus finerenone represents the emerging "triple renoprotective strategy" supported by mechanistic complementarity — RAAS inhibition targets efferent arteriolar tone and RAAS-mediated fibrosis, SGLT2 inhibition restores tubuloglomerular feedback and provides metabolic renoprotection, and finerenone blocks aldosterone-mediated inflammation and fibrosis through a non-steroidal MRA mechanism.

Option A: Option A is incorrect because polypharmacy concerns do not override evidence-based treatment additions in a patient who meets criteria; the combination is mechanistically rational and supported by trial data.
Option B: Option B is incorrect because finerenone and dapagliflozin are not contraindicated together — they have been safely co-administered in clinical trials and their volume effects are not additive in a way that produces clinically meaningful AKI risk in stable patients.
Option C: Option C is incorrect because the FIGARO-DKD trial specifically studied patients with UACR as low as 30 mg/g, and residual albuminuria of 280 mg/g in diabetic CKD remains a clinically significant target for finerenone — there is no 300 mg/g threshold for finerenone initiation in current guidance.
Option E: Option E is incorrect because finerenone and dapagliflozin have mechanistically distinct and complementary, not overlapping, renoprotective mechanisms; replacing one with the other would sacrifice the additive benefit of combination therapy that the evidence base supports.

7. A 55-year-old woman with CKD stage 4 (eGFR 24), hypertension, and no diabetes has a potassium of 5.7 mEq/L on her current regimen of fosinopril 20 mg daily, amlodipine 10 mg daily, and furosemide 40 mg twice daily. She has a UACR of 420 mg/g. Her BP is 152/90 mmHg — uncontrolled. You want to maintain her RAAS inhibitor given her proteinuria. Which management approach best addresses the hyperkalemia while preserving renoprotection?

A) Add patiromer (a potassium binder) to lower serum potassium and enable continuation of fosinopril; potassium binders are specifically indicated to enable ongoing RAAS inhibition in patients with CKD-related hyperkalemia who would otherwise require drug discontinuation, and simultaneously address the BP control gap by allowing continuation of the renoprotective regimen.
B) Discontinue fosinopril and switch to amlodipine monotherapy plus increased furosemide dose; removing the potassium-retaining agent resolves the hyperkalemia and the CCB-diuretic combination will provide adequate BP control without RAAS inhibition.
C) Add spironolactone 12.5 mg daily; despite the hyperkalemia, the anti-fibrotic benefit of dual MRA-ACEi therapy outweighs the potassium risk at this low dose in stage 4 CKD.
D) Reduce fosinopril to 10 mg daily and recheck potassium in 2 weeks; dose reduction will lower the antiproteinuric effect but will reduce potassium sufficiently to allow continuation without a potassium binder.
E) Switch fosinopril to telmisartan; ARBs cause less hyperkalemia than ACE inhibitors because they do not block bradykinin degradation, and the switch will resolve the hyperkalemia while maintaining RAAS inhibition for renoprotection.

ANSWER: A

Rationale:

Potassium binders — patiromer and sodium zirconium cyclosilicate (SZC) — were developed specifically to solve this clinical dilemma: enabling continuation of RAAS inhibition in CKD patients who develop hyperkalemia. Patiromer binds potassium in the gastrointestinal tract, reducing absorption and lowering serum potassium by 0.7–1.0 mEq/L on average, which is typically sufficient to bring potassium from 5.7 mEq/L into a safe range while maintaining full-dose fosinopril. This preserves the renoprotective benefit of RAAS inhibition in a patient with UACR 420 mg/g who clearly derives benefit from it. Simultaneously, once potassium is controlled, BP can be further addressed by uptitrating existing agents or adding additional antihypertensives.

Option B: Option B is incorrect because discontinuing fosinopril in a patient with UACR 420 mg/g and CKD stage 4 forfeits the established renoprotective benefit of RAAS inhibition — the stated goal is specifically to maintain the RAAS inhibitor, not eliminate it.
Option C: Option C is incorrect because adding spironolactone to an ACE inhibitor in a patient who is already hyperkalemic at 5.7 mEq/L with stage 4 CKD would compound the hyperkalemia dramatically and is contraindicated; this is not an acceptable approach regardless of dose.
Option D: Option D is incorrect because reducing the fosinopril dose reduces its antiproteinuric effect without certainty of achieving adequate potassium control, and a potassium binder can achieve both goals — maintained full-dose renoprotection and controlled potassium — more effectively.
Option E: Option E is incorrect because hyperkalemia risk is class-wide for all RAAS inhibitors — both ACE inhibitors and ARBs raise potassium through the same downstream mechanism (reduced aldosterone secretion); the distinction that ACE inhibitors "cause more hyperkalemia because of bradykinin" is pharmacologically inaccurate — bradykinin accumulation is responsible for cough, not hyperkalemia.

8. A 68-year-old man with CKD stage 3b (eGFR 36), hypertension, and type 2 diabetes develops a lower respiratory tract infection requiring a 7-day course of clarithromycin. He is currently on telmisartan 80 mg daily, amlodipine 10 mg daily, torsemide 20 mg daily, and metformin 500 mg twice daily. Which of the following medication management steps is most appropriate during his acute illness?

A) Continue all medications unchanged; antibiotic therapy for respiratory infections does not interact with any of his antihypertensive agents and no dose adjustments are required during a 7-day course.
B) Hold telmisartan only for the duration of the clarithromycin course; clarithromycin is a CYP3A4 inhibitor that significantly increases telmisartan plasma concentrations through reduced first-pass metabolism, creating a risk of severe hypotension.
C) Hold telmisartan and torsemide during the acute febrile illness if oral intake is significantly reduced, hold metformin due to the risk of lactic acidosis during acute illness with potential hemodynamic compromise and reduced renal perfusion, and monitor renal function closely; clarithromycin does not significantly interact with telmisartan pharmacokinetically, but the sick day guidance for RAAS inhibitors and diuretics applies.
D) Hold clarithromycin and substitute azithromycin; macrolide antibiotics as a class are contraindicated with RAAS inhibitors due to additive hyperkalemia through mineralocorticoid receptor effects, and azithromycin has a more favorable interaction profile in CKD.
E) Hold amlodipine only; clarithromycin is a potent CYP3A4 inhibitor that dramatically increases amlodipine plasma concentrations through reduced hepatic metabolism, creating a life-threatening risk of calcium channel blocker toxicity requiring drug suspension for the full antibiotic course plus 5 days.

ANSWER: C

Rationale:

This question integrates two important management considerations: sick day guidance for RAAS inhibitors and diuretics, and drug interactions with clarithromycin. The sick day guidance is the dominant clinical priority — during a febrile illness with potential for reduced oral intake, vomiting, or dehydration, telmisartan and torsemide should be held to prevent hemodynamic AKI in a patient with CKD stage 3b. Metformin should also be held during significant acute illness in CKD due to the risk of lactic acidosis if renal perfusion is compromised and metformin clearance is reduced. Regarding the clarithromycin interaction: while clarithromycin is indeed a potent CYP3A4 inhibitor, telmisartan is not metabolized by CYP3A4 — it undergoes direct glucuronidation. Amlodipine is a CYP3A4 substrate and clarithromycin does increase amlodipine exposure, but the degree of interaction in clinical practice is generally moderate and does not typically require routine drug suspension for a short course in a monitored patient. The principal management priority is sick day guidance.

Option A: Option A is incorrect because sick day guidance for RAAS inhibitors, diuretics, and metformin during acute illness is an established patient safety intervention in CKD — continuing all medications unchanged in a febrile patient with reduced oral intake risks AKI and lactic acidosis.
Option B: Option B is incorrect in its pharmacokinetic reasoning — telmisartan is not a CYP3A4 substrate; the interaction described does not apply.
Option D: Option D is incorrect because macrolide antibiotics do not cause hyperkalemia through mineralocorticoid receptor effects — this is a fabricated mechanism; the interaction concern with clarithromycin is CYP3A4 inhibition affecting co-administered substrates, not MR effects.
Option E: Option E is incorrect because while the clarithromycin-amlodipine CYP3A4 interaction is real and does increase amlodipine exposure, a 7-day course does not typically require complete suspension of amlodipine in clinical practice — monitoring for increased peripheral edema or hypotension is appropriate, but this is not the most important management step for this patient.

9. A 70-year-old man with CKD stage 5 (eGFR 12, not yet on dialysis) and hypertension has a BP of 178/96 mmHg. He is on amlodipine 10 mg daily and furosemide 80 mg twice daily. His potassium is 5.4 mEq/L and he has 2+ bilateral leg edema. His nephrologist wants to add a RAAS inhibitor for cardiovascular protection and residual renal function preservation. Which of the following best describes the approach to RAAS inhibitor use at this stage?

A) RAAS inhibitors are absolutely contraindicated in CKD stage 5 pre-dialysis — at eGFR below 15 all RAAS inhibitors must be stopped because the risk of complete anuria from efferent arteriolar dilation is unacceptably high.
B) RAAS inhibitor therapy can be initiated cautiously at low dose if potassium can be controlled to below 5.0 mEq/L — consider adding a potassium binder first, then starting telmisartan or fosinopril at a low dose with very close monitoring of creatinine and potassium within 1–2 weeks; the benefit-risk calculation favors attempting RAAS inhibition for cardiovascular and residual renal function protection even at this eGFR if potassium is manageable.
C) Only loop diuretics should be added at this stage; RAAS inhibitors provide no benefit in pre-dialysis CKD stage 5 because there is insufficient residual nephron mass for efferent dilation to produce meaningful renoprotection.
D) Add spironolactone 25 mg daily as the RAAS inhibitor of choice in stage 5 pre-dialysis CKD; MRAs are preferred over ACE inhibitors and ARBs at eGFR below 15 because they do not affect efferent arteriolar tone and therefore do not risk acute GFR reduction.
E) Double the furosemide dose to 160 mg twice daily before adding any RAAS inhibitor; adequate diuresis must first bring potassium below 4.0 mEq/L before RAAS inhibition is safe in stage 5 CKD.

ANSWER: B

Rationale:

RAAS inhibition in CKD stage 5 pre-dialysis requires careful individualized assessment but is not absolutely contraindicated. The benefit-risk calculation at this stage still favors RAAS inhibitor use in appropriate patients: cardiovascular risk is extremely high in pre-dialysis CKD, and RAAS inhibition provides cardiovascular protection and may help preserve residual renal function — which has significant survival value in the pre-dialysis period (residual urine output contributes to volume control, solute clearance, and quality of life). The approach requires careful management of hyperkalemia (potassium binders are particularly important at this stage) and very close monitoring. The preferred agents in advanced CKD are fosinopril (dual elimination) or telmisartan (biliary elimination), started at very low doses. If potassium cannot be controlled despite binders and dietary restriction, the benefit-risk calculation may ultimately favor withholding RAAS inhibition.

Option A: Option A is incorrect because RAAS inhibitors are not absolutely contraindicated in CKD stage 5 pre-dialysis — this overstates the restriction; the decision is individualized and supported by guidelines as described. Complete anuria from efferent dilation is an extreme and rare outcome, not a predictable consequence at low doses with close monitoring.
Option C: Option C is incorrect because residual nephron function preservation and cardiovascular protection remain relevant goals even at eGFR 12; dismissing RAAS inhibitor benefit at this stage is not supported by evidence or guidelines.
Option D: Option D is incorrect because spironolactone in CKD stage 5 carries very high hyperkalemia risk and is not a preferred or appropriate substitute for ACE inhibitors or ARBs at this stage; it does not exert its renoprotective effects through the same pathway and is not recommended as first-choice RAAS inhibition in pre-dialysis stage 5.
Option E: Option E is incorrect because a target potassium below 4.0 mEq/L through aggressive diuresis is not the standard prerequisite threshold, and doubling furosemide in a patient with 5.4 mEq/L potassium already risks over-diuresis, volume depletion, and precipitating AKI before RAAS inhibition is even started.

10. A 44-year-old woman with autosomal dominant polycystic kidney disease (ADPKD) and CKD stage 3a (eGFR 58) presents with BP 148/92 mmHg and UACR 85 mg/g. She has no diabetes. She asks about the best antihypertensive approach for her specific condition. Which of the following best describes evidence-based antihypertensive management in ADPKD-related CKD?

A) Calcium channel blockers are the preferred first-line agent in ADPKD because cyst expansion is driven by calcium-dependent mTOR signaling, and CCBs directly inhibit cyst growth by blocking the calcium entry that drives this pathway.
B) Beta-blockers are the treatment of choice in ADPKD hypertension because the renin-angiotensin system is not activated in this condition — the hypertension is purely mechanical from cyst compression of renal vasculature, and sympatholysis with beta-blockade is the most effective antihypertensive strategy.
C) Diuretics are contraindicated in ADPKD because the cysts in collecting duct epithelium are stimulated by vasopressin, and diuretics trigger compensatory vasopressin release that accelerates cyst growth — tolvaptan is the only agent that safely lowers BP in ADPKD without this risk.
D) No antihypertensive treatment is necessary in ADPKD until eGFR falls below 30 — early BP control does not affect the rate of kidney enlargement or GFR decline in this condition, and treating hypertension before this threshold exposes patients to medication adverse effects without benefit.
E) ACE inhibitors or ARBs are the preferred first-line agents in ADPKD-related hypertension — RAAS activation through cyst compression of intrarenal vasculature is a key driver of hypertension in ADPKD, and RAAS inhibition addresses the underlying mechanism while providing renal vascular protection; the HALT-PKD trial demonstrated that intensive BP control targeting below 110/75 mmHg with ACE inhibition slowed total kidney volume growth and reduced left ventricular mass index in early ADPKD.

ANSWER: E

Rationale:

ADPKD is associated with early and prominent RAAS activation — cyst expansion compresses intrarenal vasculature, activating juxtaglomerular cells to release renin and sustain elevated angiotensin II levels even before significant GFR decline. This renin-dependent hypertension responds particularly well to RAAS inhibition, which also addresses the intraglomerular pressure and renal vascular injury that accompanies cyst growth. The HALT-PKD trial demonstrated that in early ADPKD (eGFR above 60), intensive BP control targeting 95–110/60–75 mmHg using ACE inhibitor-based therapy significantly slowed total kidney volume growth and reduced left ventricular mass index compared to standard control targeting 120–130/70–80 mmHg — providing mechanistic and outcome evidence for ACE inhibitor-based treatment in ADPKD-related hypertension.

Option A: Option A is incorrect because CCBs do not directly inhibit mTOR signaling or cyst growth in clinically relevant ways; the pharmacological pathway described is not the basis for antihypertensive therapy in ADPKD, and CCBs are not preferred first-line agents for this condition.
Option B: Option B is incorrect because RAAS activation — not purely mechanical cyst compression — is the dominant mechanism of ADPKD hypertension; sympatholysis with beta-blockade is not the mechanistically preferred or evidence-based strategy.
Option C: Option C is incorrect because while vasopressin does drive cyst growth in ADPKD (the basis for tolvaptan therapy), diuretics are not contraindicated in ADPKD — vasopressin's effect on cysts operates through V2 receptor signaling, which is the specific target of tolvaptan, not a generic consequence of any diuretic-triggered vasopressin release.
Option D: Option D is incorrect because early BP control in ADPKD is recommended — the HALT-PKD trial enrolled patients with eGFR above 60 and demonstrated benefit of early intensive BP control on kidney volume and cardiac outcomes.

11. A 59-year-old man with CKD stage 3b (eGFR 34), type 2 diabetes, and hypertension is well-controlled on losartan 100 mg daily, amlodipine 10 mg daily, and empagliflozin 10 mg daily. His BP is 124/76 mmHg, UACR is 180 mg/g, potassium is 4.1 mEq/L, and HbA1c is 7.1%. He is scheduled for elective coronary angiography with iodinated contrast next week. Which of the following represents the most appropriate perioperative medication management?

A) Continue all medications unchanged through the procedure — modern iodinated contrast agents have minimal nephrotoxicity in patients with CKD stage 3b and no perioperative dose adjustments are required for losartan, empagliflozin, or amlodipine.
B) Hold losartan 48 hours before the procedure only; ACE inhibitors and ARBs cause intraoperative hypotension due to blunted angiotensin II response during contrast-induced hemodynamic changes, but other medications can be continued.
C) Hold empagliflozin at least 3–4 days before the procedure to reduce the risk of euglycemic diabetic ketoacidosis (eKDA) associated with SGLT2 inhibitor use in the perioperative period, hold losartan on the day of and the day after the procedure to reduce the risk of contrast-induced AKI in CKD, ensure adequate pre-hydration, and restart both agents once oral intake is restored and creatinine is stable.
D) Hold amlodipine 24 hours before the procedure — calcium channel blockers interfere with contrast dye clearance through competitive inhibition of renal organic anion transporters, significantly increasing contrast nephrotoxicity risk in CKD patients.
E) Switch empagliflozin to insulin therapy permanently before the procedure; SGLT2 inhibitors are permanently contraindicated after iodinated contrast exposure in CKD patients because contrast permanently impairs SGLT2 transporter function in the proximal tubule.

ANSWER: C

Rationale:

Two distinct perioperative concerns apply to this patient's medications. First, empagliflozin: SGLT2 inhibitors are associated with euglycemic diabetic ketoacidosis (eKDA) in the perioperative/periprocedural setting, particularly when oral intake is restricted, carbohydrate intake is reduced, or physiological stress increases counter-regulatory hormones. Most guidelines and professional societies (ADA, ESC, EASD) recommend holding SGLT2 inhibitors at least 3 days (some recommend 3–4 days given their pharmacokinetic profile) before elective procedures involving contrast or anaesthesia and restarting only when oral intake is well-established. Second, losartan: RAAS inhibitors in the setting of iodinated contrast and CKD increase the risk of contrast-induced AKI by reducing the renal perfusion reserve; holding losartan on the day of and day after the procedure, combined with adequate pre-hydration (the most evidence-based intervention for contrast nephropathy prevention), is a reasonable risk-mitigation strategy. Amlodipine does not require perioperative suspension for any of the reasons listed.

Option A: Option A is incorrect because both empagliflozin and losartan have specific perioperative management considerations that require action, not continuation unchanged — particularly the SGLT2 inhibitor eKDA risk.
Option B: Option B is incorrect because holding only losartan 48 hours before misses the critical empagliflozin safety concern and the timing of losartan holding is not specifically 48 hours before — the day of and day after is the more standard guidance for RAAS inhibitors with contrast procedures.
Option D: Option D is incorrect because amlodipine does not inhibit renal organic anion transporters or impair contrast clearance; this mechanism is pharmacologically fabricated.
Option E: Option E is incorrect because iodinated contrast does not permanently impair SGLT2 transporter function; this is a non-existent mechanism, and SGLT2 inhibitors are absolutely not permanently contraindicated after contrast exposure — they are held temporarily and restarted after the procedure.